Literature DB >> 7045395

Demonstration of biological activity and nucleotide sequence of an in vitro synthesized clone of the Moloney murine sarcoma virus mos gene.

D J Donoghue.   

Abstract

A clone of the Moloney murine sarcoma virus mos gene derived by in vitro reverse transcription was characterized. When assayed for focus formation by DNA transfection on NIH/3T3 cells, this clone was biologically inactive, presumably due to the absence of a long terminal repeat sequence. Therefore, a long terminal repeat was inserted into the clone by in vitro recombination, after which the most gene was able to transform NIH/3T3 cells efficiently. The nucleotide sequence encompassing the transforming region of this clone was determined. A single long open reading frame was observed, which potentially encodes a polypeptide of 41,000 daltons. This open reading frame initiates with the first five amino acids of the murine leukemia virus env gene, after which it enters the mos sequence, where it terminates. The nucleotide sequence described in this paper was compared with other sequences of mos in an effort to resolve discrepancies in the position of the long open reading frame. Although Moloney murine sarcoma virus retains the 3' splicing site of the murine leukemia virus env gene, a mos-specific mRNA which corresponds structurally to the murine leukemia virus env mRNA was not identified. The sequence described here revealed a single nucleotide change in the proposed env gene 3' splicing site which was retained in Moloney murine sarcoma virus. This deviation from the consensus 3' splicing sequence may underlie the observed absence of mos expression via the env gene splicing pathway.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7045395      PMCID: PMC256880     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase.

Authors:  F Sanger; A R Coulson
Journal:  J Mol Biol       Date:  1975-05-25       Impact factor: 5.469

2.  Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids.

Authors:  A J Berk; P A Sharp
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

3.  Evidence for helper independent murine sarcoma virus. I. Segregation of replication-defective and transformation-defective viruses.

Authors:  J Ball; J A McCarter; S M Sunderland
Journal:  Virology       Date:  1973-11       Impact factor: 3.616

4.  A virus-induced rhabdomyosarcoma of mice.

Authors:  J B Moloney
Journal:  Natl Cancer Inst Monogr       Date:  1966-09

5.  Nucleotide sequence of the intercistronic region between genes G and F in bacteriophage phiX174 DNA.

Authors:  J C Fiddes
Journal:  J Mol Biol       Date:  1976-10-15       Impact factor: 5.469

6.  Separation of sarcoma virus-specific and leukemia virus-specific genetic sequences of Moloney sarcoma virus.

Authors:  E M Scolnick; R S Howk; A Anisowicz; P T Peebles; C D Scher; W P Parks
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

7.  Relationship between Moloney murine leukemia and sarcoma virus RNAs: purification and hybridization map of complementary DNAs from defined regions of Moloney murine sarcoma virus 124.

Authors:  D Dina; K Beemon
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

8.  Nucleotide sequences in mouse DNA and RNA specific for Moloney sarcoma virus.

Authors:  A E Frankel; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

9.  A heteroduplex study of the sequence relationships between the RNAs of M-MSV and M-MLV.

Authors:  S Hu; N Davidson
Journal:  Cell       Date:  1977-03       Impact factor: 41.582

10.  Viable molecular hybrids of bacteriophage lambda and eukaryotic DNA.

Authors:  M Thomas; J R Cameron; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1974-11       Impact factor: 11.205

View more
  11 in total

1.  v-mos protein produced by in vitro translation has protein kinase activity.

Authors:  N K Herzog; M Nash; L S Ramagli; R B Arlinghaus
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 2.  Onc genes and other new targets for cancer chemotherapy.

Authors:  H Busch
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 3.  Molecular lesions in cancer.

Authors:  H Busch
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

4.  Molecular basis underlying phenotypic revertants of Moloney murine sarcoma virus MuSVts110.

Authors:  P E Cizdziel; M A Nash; D G Blair; E C Murphy
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

5.  Biologically active mutants with deletions in the v-mos oncogene assayed with retroviral vectors.

Authors:  R J Bold; D J Donoghue
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

6.  Comparison of myeloproliferative sarcoma virus with Moloney murine sarcoma virus variants by nucleotide sequencing and heteroduplex analysis.

Authors:  A Stacey; C Arbuthnott; R Kollek; L Coggins; W Ostertag
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

7.  Molecular cloning and characterization of a leukemia-inducing myeloproliferative sarcoma virus and two of its temperature-sensitive mutants.

Authors:  R Kollek; C Stocking; F Smadja-Joffe; W Ostertag
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

8.  In vitro methylation of specific regions of the cloned Moloney sarcoma virus genome inhibits its transforming activity.

Authors:  M L McGeady; C Jhappan; R Ascione; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1983-03       Impact factor: 4.272

9.  Lysine residue 121 in the proposed ATP-binding site of the v-mos protein is required for transformation.

Authors:  M Hannink; D J Donoghue
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Detection of an 85,000-dalton phosphoprotein in ts110 murine sarcoma virus-infected cells with antiserum against a v-mos peptide.

Authors:  J Papkoff; T Hunter
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.